Search

Chairs and Members

Chair (re-appointment, 2023–2026)Josef Vormoor—Professor of Hematological Malignancies in Children, University Medical Center Utrecht (The Netherlands)

Co-chair (re-appointment, 2023–2026)Maria Ester Bernardo—Clinical Coordinator, Clinical Research Unit, San Raffaele Telethon Institute for Gene Therapy (Italy)

SWG Steering Committee members (2024–2027 term)
SWG Secretary—Francesco Saglio, AOU Città…

Read more

GoCART coalition activities (CARTs and cellular therapies)

GoCART Clinical Case Discussion Series for Physicians - 4th edition
Panel: Dr. Sara Ghorashian, Dr. Peter Bader and Dr. Franco Locatelli along with moderator Dr.

Read more

Selected EMA news

November 2024New medicines recommended for approval
Eltrombopag Viatris (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C (disease in which patients have low levels of blood platelets)

Alhemo (concizumab)
Prevention of bleeding in patients with hemophilia A…

Read more

Other COVID-19 Resources

Safety of COVID-19 vaccines – April updates

ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines

EMA recommends authorisation of COVID-19 medicine Evusheld

EMA recommends authorisation of booster doses of Comirnaty from 12 years of age

EMA recommends approval of Spikevax…

Read more

EHA and PTHiT Successfully Conclude the Second Joint Virtual Mini Hematology Tutorial

EHA-PTHiT Mini Hematology Tutorial

November 15-16, 2021

Meeting chairs:

Prof G Gaidano (European Hematology Association)
Prof I Hus (Polish Society of Hematology and Transfusion)
Prof T Robak (Polish Society of Hematology and Transfusion) 
After a successful mini Tutorial in April 2021, EHA and PTHiT decided to…

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more